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ABSTRACT
Objectives: CTNNB1 exon 3 mutations have shown 
independent prognostic value in endometrial cancer. We 
aimed to assess whether nuclear β-catenin expression is an 
accurate surrogate, as immunohistochemistry is cheaper, 
faster, and more widely applicable than sequencing.
Methods: A systematic review was performed by 
searching electronic databases for all studies assessing 
the association between β-catenin immunohistochemical 
expression and CTNNB1 mutations. Meta-analysis 
of diagnostic accuracy was performed by calculating 
sensitivity, specificity, positive and negative likelihood 
ratios (LR+ and LR–), diagnostic odds ratio (DOR), 
and area under the curve (AUC) on summary receiver 
operating characteristic curves.
Results: Fifteen observational studies with 1,158 
endometrial carcinomas were included. Pooled estimates 
showed sensitivity = 0.88, specificity = 0.85, LR+ = 4.57, 
LR– = 0.20, DOR = 27.16, and high diagnostic accuracy 
(AUC = 0.91).
Conclusions: Nuclear expression of β-catenin is an 
accurate immunohistochemical surrogate of CTNNB1 
exon 3 mutations and thus might be considered in the risk 
stratification of endometrial cancer.
Endometrial cancer (EC) is the most common gyne-
cologic malignancy in the Western world, with an increase 
in both incidence and mortality rates in the past years.1
Most patients at a low stage have good outcomes and 
are eligible for conservative treatment in many cases, but 
patients with advanced stages or more aggressive tumor 
histotypes show poor prognosis.2,3 The major cause of 
increased mortality is a risk stratification that is still based 
on poor reproducible histologic examination, which has 
led to over- and undertreatment of patients.4,5
In the 2013, The Cancer Genome Atlas (TCGA) 
identified four distinct molecular categories of EC that 
correlated with the prognosis. The first category in-
cluded endometrioid ECs with a very high mutational 
rate (“ultra-mutated group”); ECs in this group har-
bored mutations in the polymerase-ε (POLE) exonu-
clease domain and showed good prognosis. The second 
category was constituted by microsatellite-instable endo-
metrioid EC with a varying grade, a high mutational rate 
(“hyper-mutated group”), and an intermediate prognosis. 
The third category included low-grade endometrioid ECs 
with a low mutational rate and a low somatic copy number 
alterations rate (“copy number–low group”), with good 
to intermediate prognosis. The fourth category showed 
a low mutational rate but a high somatic copy number 
alterations rate (“copy number–high group”) and TP53 
mutations; this group was mainly constituted by serous 
EC and showed poor prognosis.2,6-8
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Subsequent studies have refined the molecular/prog-
nostic classification, demonstrating that high expres-
sion of L1CAM, lymphovascular space invasion, and 
CTNNB1 (β-catenin–encoding gene) exon 3 mutations 
have an independent prognostic value.9-11 All these find-
ings have pointed out that the traditional systems for risk 
stratification of EC cause many patients to be over- or 
undertreated.2,7,8 Therefore, a molecular definition of 
EC specimens appears necessary to choose an adequate 
treatment. Unfortunately, techniques used to identify 
genomic subgroups, including genome sequencing, have 
been expensive, complex, and unsuitable for wide clinical 
application.2
This has led to an increasing interest in immuno-
histochemical surrogates of molecular prognostic mark-
ers.8 Immunohistochemistry is cheaper, faster, and more 
widely available than sequencing analyses.12-16 In fact, ab-
normal immunohistochemical expression of p53 protein 
and of mismatch-repair proteins seems to be a reliable 
surrogate for TP53 mutations and microsatellite insta-
bility, respectively.2,7,8
Regarding CTNNB1, nuclear accumulation of β-cat-
enin has been proposed as an immunohistochemical sur-
rogate of exon 3 mutations, but the accuracy of such a 
method is not well defined.
The objective of our study was to assess the diag-
nostic accuracy of β-catenin nuclear accumulation as 
an immunohistochemical surrogate for CTNNB1 exon 3 
mutations. We aimed to define if  immunohistochemistry 
for β-catenin may be introduced as a reliable test for the 
prognostic stratification of EC.
Materials and Methods
Methods for electronic search, study selection, risk 
of bias assessment, extraction, and analysis of data were 
defined a priori. Two authors (A.T. and A.R.) independ-
ently performed all review stages. Disagreements were re-
solved by discussion with a third author (G.S.). This study 
was reported following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses statement17 and 
the Synthesizing Evidence from Diagnostic Accuracy 
Tests (SEDATE) guidelines.18
MEDLINE, Scopus, EMBASE, Web of Sciences, 
Cochrane Library, ClinicalTrial.gov, and Google Scholar 
were searched from their inception to September 2018 
by using a combination of the following text words and 
all their synonyms found on Medical Subject Headings 
vocabulary: beta-catenin, β-catenin, CTNNB1, exon 3, 
endometrial cancer, endometrioid adenocarcinoma, endo-
metrium, immunohistochemical, immunohistochemistry, 
prognosis, marker, Atlas, cancer, genome, TCGA, 
PORTEC, ProMisE, Proactive Molecular Risk Classifier, 
and TransPORTEC. Relevant references from each 
selected study were also assessed.
All peer-reviewed, prospective, or retrospective 
studies assessing the association between β-catenin immu-
nohistochemical expression and CTNNB1 mutations 
were included in the systematic review. Studies not allow-
ing comparisons between immunohistochemistry and 
molecular analysis were excluded. In case of overlapping 
data between two studies (ie, same institution and period 
of enrollment, same immunohistochemical and molec-
ular results), the study assessing the smaller patient series 
was excluded.
The risk of bias among studies was assessed ac-
cording to the revised Quality Assessment of Diagnostic 
Accuracy Studies 2.19 For each study, four domains related 
to the risk of bias were assessed: (1) patient selection (ie, if  
the patients were consecutive or randomly selected from a 
consecutive series), (2) index test (ie, if  the criteria used to 
assess β-catenin expression were clearly defined), (3) ref-
erence standard (ie, if  the methods for molecular analysis 
were appropriate), and (4) flow and timing (ie, if  patients 
were not inappropriately excluded from the index test or 
reference standard). Reviewers’ judgments were “low risk,” 
“unclear risk,” or “high risk of bias” for each domain.
Concerns about applicability were also evaluated for 
domains 1, 2 and 3 (ie, if  the criteria used are correct but 
do not fit the objective of our review).
Original data were not modified during extraction. 
Two-by-two contingency tables were prepared for each 
study. Two qualitative variables were reported in the tables. 
The first variable (which was the index test) was β-catenin 
expression, dichotomized as “nuclear” vs “membranous/
cytoplasmic.” The second variable (which was the refer-
ence standard) was CTNNB1 mutational status, dichoto-
mized as “mutated (mt)” vs “wild type (wt).”
For the index test, any striking nuclear β-catenin 
staining was considered “nuclear.” Weak nuclear expres-
sion—defined as a light brown nuclear nuance—was 
lumped together with “membranous/cytoplasmic,” as it 
may occur in normal endometrium.20 For the reference 
test, only mutations in exon 3 of the CTNNB1 gene were 
considered.
CTNNB1-mt cancers with nuclear β-catenin were 
considered as true positive, CTNNB1-wt cancers with 
membranous/cytoplasmic β-catenin as true negative, 
CTNNB1-wt cancers with nuclear β-catenin as false pos-
itive, and CTNNB1-mt cancers with membranous/cyto-
plasmic β-catenin as false positive.
Sensitivity, specificity, positive and negative like-
lihood ratios, and diagnostic odds ratio (DOR) were 
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calculated for each study and as a pooled estimate. Values 
were reported graphically on forest plots with 95% confi-
dence intervals (CIs).
Statistical heterogeneity among the included studies 
was evaluated using the Higgins I2 statistic; heteroge-
neity was categorized as null for I2  =  0%, minimal for 
0%  <  I2  ≤  25%, low for 25%  <  I2  ≤  50%, moderate for 
50% < I2 ≤ 75%, and high for I2 > 75%.
The random-effect model of DerSimonian and Laird 
was used independently from the heterogeneity, as recom-
mended by the SEDATE guidelines.18
Area under the curve (AUC) was calculated on sum-
mary receiver operating characteristic curves. The diag-
nostic usefulness was categorized as absent for AUC ≤ 0.5, 
low for 0.5 < AUC ≤ 0.75, moderate for 0.75 < AUC ≤ 0.9, 
high for 0.9 < AUC < 0.97, and very high for AUC ≥ 0.97.
The data analysis was performed using Meta-DiSc 
version 1.4 (Clinical Biostatistics Unit, Ramon y Cajal 
Hospital) and Review Manager 5.3 (The Nordic Cochrane 
Centre, Cochrane Collaboration, 2014).
Results
Fifteen observational studies with 1,158 patients were 
included. The process of study selection is reported in 
❚Figure 1❚.
Most ECs (82%) were endometrioid adenocarcinoma. 
Histologic specimens were obtained by hysterectomy in 
13 studies and by biopsy in one study, while in the other 
one, the sampling method was unspecified. DNA or RNA 
was obtained from fresh-frozen tissue in two studies, from 
paraffin-embedded tissue in 10 studies, and from either 
the former or the latter in two studies. Molecular analysis 
included polymerase chain reaction and exon 3 sequenc-
ing in all studies; in one study, next-generation sequenc-
ing (NGS) was performed. Single-strand conformation 
polymorphism was performed as a screening test in five 
studies.
Characteristics of the included studies are reported 
in ❚Table 1❚.
For the “patient selection” domain, all studies were 
considered at a low risk of bias. Concerns were consid-
ered unclear for seven studies (selection restricted to EC 
with synchronous ovarian cancer,24,33 EC with coexisting 
endometrial hyperplasia,26 EC with squamous differenti-
ation,27 EC treated with progestin,30 and tamoxifen-asso-
ciated EC31).
For the “index test” domain, three studies were 
considered at unclear risk of bias (criteria for β-catenin 
evaluation not completely clarified); high concerns were 
found for two studies (cytoplasmic expression of β-cat-
enin lumped together with nuclear expression in the 
results).21,22
For the “reference standard” domain, neither sig-
nificant risks of bias nor concerns about applicability 
were found.
For the “flow and timing” domain, two studies were 
considered at unclear risk of bias, because causes of the 
exclusion of some patients from immunohistochemical23 
or molecular analysis20 were not specified.
All the remaining judgments were “low risk of bias.”
Results of risk of bias assessment are summarized in 
❚Figure 2❚.
Nuclear expression of β-catenin showed a pooled 
sensitivity of 0.88 (95% CI, 0.81-0.93), with minimal het-
erogeneity among studies (I2 = 17.8%). Pooled specificity 
was 0.85 (95% CI, 0.81-0.88) with moderate heterogeneity 
(I2 = 59.9%). Pooled positive and negative likelihood ratios 
were 4.57 (95% CI, 3.04-6.87) and 0.20 (95% CI, 0.14-0.30), 
respectively, with moderate heterogeneity (I2 = 53.4%) and 
no heterogeneity (I2 = 0%), respectively ❚Figure 3❚. Pooled 
DOR was 27.16 (95% CI, 12.87-57.33), with minimal het-
erogeneity (I2  =  3.5%). The overall diagnostic accuracy 
was high, with an AUC of 0.91 ❚Figure 4❚.
Discussion
Our study showed that nuclear expression of β-cat-
enin was an accurate immunohistochemical surrogate of 
CTNNB1 exon 3 mutations in EC. To our knowledge, this 
may be the first systematic review and meta-analysis on 
this topic.
❚Figure 1❚ Flow diagram of studies identified in the sys-
tematic review (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses template).
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Our results may implement the research for immu-
nohistochemical surrogates of  molecular analysis, indis-
pensable to make applicable the TCGA classification of 
EC. In fact, this reclassification has been demonstrated 
to reduce under- and overtreatment of  patients with 
EC but appears limited by prohibitive costs and tech-
nical complexity of  analysis.2 These problems should be 
solved to address the increased mortality of  EC, which 
is now a global health problem.1 Indeed, the major 
cause of  this increased mortality seems to be linked to 
a risk stratification of  EC based on histologic examina-
tion of  surgical specimens. This examination is affected 
by poor reproducibility, even when assessed by expert 
pathologists.4,5,34,35 Moreover, the poor reproducibility 
seems to regard the endometrium even more than other 
tissues.36,37 β-Catenin is encoded by the CTNNB1 gene 
B
A
❚Figure 2❚ A, Assessment of risk of bias. Summary of risk of bias for each study. Plus sign: low risk of bias; minus sign: high 
risk of bias; question mark: unclear risk of bias. B, Risk of bias graph about each risk of bias item presented as percentages 
across all included studies.
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and is a key protein in Wnt signaling pathway. β-Catenin 
acts as a membrane link between cell-cell adherens junc-
tions and cytoskeleton. Activation of  the Wnt pathway 
makes β-catenin accumulate first into the cytoplasm and 
then into the nucleus, where it binds to transcription 
factors of  the LEF/TCF family, favoring cell prolifer-
ation. Pathologic activation of  this pathway can lead to 
cancerous transformation.38,39
As an oncogenic protein, β-catenin is known to be 
involved in endometrial carcinogenesis.6,39 Mutations in 
Pooled specificity
Pooled negative LR
❚Figure 3❚ Forest plots reporting sensitivity, specificity, and positive and negative likelihood ratios for each study and as 
pooled estimates, with 95% confidence interval.
A B
❚Figure 4❚ A, Forest plot reporting diagnostic odds ratio for each study and as pooled estimate, with 95% confidence interval. 
B, Area under the curve (AUC) calculated on summary receiver operating characteristic curves. AUC = 0.9088; SE = 0.0244. 
Cochran-Q = 0.8407; SE = 0.0268.
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CTNNB1 occur in about half  of ECs with a low muta-
tional rate, a low somatic copy number alteration, and 
TP53-wt (“copy number–low group”), which constitute 
the largest group in the TCGA classification.6 Contrary 
to the other groups, this group lacks a molecular signa-
ture and shows a heterogeneous prognosis.6,8 An analysis 
of the Post Operative Radiation Therapy in Endometrial 
Carcinoma  (PORTEC) cohort showed that mutations 
in exon 3 of CTNNB1 identified a subset at higher risk 
within this group. In particular, in the absence of other 
prognostic factors, CTNNB1 mutations made the prog-
nosis switch from good to intermediate.9 Other studies 
confirmed the independent prognostic significance of 
CTNNB1 exon 3 mutations.10,11 Therefore, some authors 
have considered CTNNB1-mt EC a separate molecular 
and prognostic group.8
Nuclear accumulation of β-catenin has been given 
interest as a possible immunohistochemical surrogate 
of CTNNB1 mutations. However, its accuracy has never 
been defined. Recently, Kim et  al12 performed a mo-
lecular and immunohistochemical analysis of 99 ECs, 
showing that nuclear β-catenin had a sensitivity of 0.85 
and a specificity of 1.00 in identifying CTNNB1 exon 3 
mutations. They were the first authors to perform such 
an analysis using NGS. They hypothesized the use of 
β-catenin immunohistochemistry as a screening text, fol-
lowed by CTNNB1 exon 3 sequencing only in negative or 
ambiguous cases.12 Regarding sensitivity, the value they 
found (0.85) was quite close to our result (0.88), lying in 
our 95% CI (0.80-0.87). However, the specificity observed 
in our analysis appeared lower (0.85 vs 1.00). Such a dif-
ference may be due to the higher sensitivity of NGS in 
detecting mutations compared with older techniques.40 
In previous studies, some EC specimens might have been 
considered false positive (nuclear β-catenin expression 
and CTNNB1-wt) only because the pre-NGS sequencing 
technique did not detect the mutation.
The reliability of  nuclear expression of  β-catenin as 
a surrogate of  CTNNB1 mutations was not so obvious. 
In fact, nuclear accumulation of  β-catenin may also 
occur in the absence of  CTNNB1 mutations, as can be 
observed in breast cancer.41 Evidence supports that the 
association between CTNNB1 mutations and nuclear 
expression of  β-catenin is tissue specific and influenced 
by the expression of  several other proteins.12 Therefore, 
this association needed to be defined with specific regard 
to EC tissue.
Our study demonstrates that the association between 
nuclear β-catenin and CTNNB1 mutations is particu-
larly strong in EC. We found that nuclear β-catenin was 
an accurate immunohistochemical surrogate of CTNNB1 
mutations, with an AUC of over 0.90. Such result might 
support the clinical applicability of immunohistochemis-
try for β-catenin. As the risk stratification in EC is ex-
pected to radically change in the near future, the β-catenin 
immunostaining pattern might be considered in a prog-
nostic algorithm, together with other significant factors, 
such as lymphovascular space invasion and immunohis-
tochemical expression of p53, mismatch repair proteins, 
and L1CAM. Such an algorithm might be crucial in guid-
ing adjuvant therapy, substantially reducing both under- 
and overtreatment.9 To date, the best-known prognostic 
algorithm is the Proactive Molecular Risk Classifier for 
Endometrial Cancer (ProMisE), which involves immu-
nohistochemistry for mismatch repair proteins, POLE 
sequencing, and p53 immunohistochemistry; these three 
steps allow defining four prognostic groups that superim-
pose on the four TCGA groups.2,7 In this regard, immu-
nohistochemistry for β-catenin might be introduced as an 
additional fourth step in the p53-normal group (which ba-
sically overlaps with the copy number–low TCGA group), 
identifying a subgroup at worse prognosis. A hypothetical 
integration of β-catenin immunohistochemistry in the 
ProMisE is shown in ❚Figure 5❚.
Although our results appeared promising, there 
are some concerns to address. In particular, there are 
no standardized criteria for interpretation of β-cat-
enin immunostaining. Regarding the percentage of 
stained cells, it seems that even a minimal percentage of 
❚Figure 5❚ A possible integration of immunohistochemistry 
for β-catenin in the Proactive Molecular Risk Classifier for 
Endometrial Cancer as an additional fourth step. Green indi-
cates good prognosis; yellow indicates intermediate prog-
nosis; red indicates poor prognosis. POLE, polymerase-ε.
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β-catenin–positive nuclei should be considered significant; 
indeed, CTNNB1-mt ECs may show even only few β-cat-
enin–stained nuclei.12 With respect to intensity of immu-
nostaining, weak nuclear expression, appearing as a light 
brown nuance in the nucleus, may be observed in normal 
endometrium in the proliferative phase.20 Therefore, it 
seems that only a nuclear expression at least moderate—
appearing as a striking brown staining at immunohisto-
chemistry—should be considered significant, as suggested 
by several authors.21-23 On the other hand, weak nuclear 
expression might be considered nonsignificant or at least 
ambiguous ❚Image 1❚.
Our results might also be affected by differences 
in methods of tissue withdrawal (eg, fresh tissue or 
microdissected tissue) for DNA extraction, as well as in 
the sensitivity of sequencing analysis, as discussed above.
Future studies should confirm whether immunohisto-
chemistry for β-catenin may be routinely used for the risk 
stratification of EC. For this purpose, the definition of stan-
dardized criteria for interpreting β-catenin immunostaining 
and the use of NGS as reference standard are advised.
Conclusions
Immunohistochemical nuclear expression of β-cat-
enin appears as an accurate surrogate of CTNNB1 exon 3 
mutations; therefore, it might be used as a less expensive 
❚Image 1❚ Different patterns of β-catenin immunohistochemical expression (×600). A, Absence of nuclear expression (no 
nuclear brown staining). B, Weak nuclear expression (light brown nuclear nuance). C, Moderate to strong nuclear expression 
(brown to dark brown nuclear staining).
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prognostic marker in EC. Recent evidence suggests that 
the accuracy of β-catenin immunohistochemistry may be 
even higher if  NGS is used as reference standard, with a 
virtual specificity of 100%.
Further studies are necessary to confirm the prog-
nostic value and the clinical applicability of immunohis-
tochemistry for β-catenin in the risk stratification in EC. 
For this purpose, standardized criteria for the interpre-
tation of immunostaining should be defined, and NGS 
should be used as reference standard.
Corresponding author: Antonio Raffone, MD; anton.raffone@
gmail.com.
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